The Relationship Between Donepezil and Behavioral Disturbances in Patients With Alzheimer's Disease

The authors tested the hypothesis that behavioral disturbances are reported at significantly lower rates by caregivers of Alzheimer's disease (AD) patients receiving the antidementia drug donepezil, compared with a group of patients receiving no antidementia drug treatment. Patients administered donepezil for 6 months (n = 84) were compared with patients not on donepezil (n = 248). Patients taking donepezil had significantly lower levels of behavioral disturbances than patients not receiving this agent (P≤0.01). Specifically, donepezil patients were described as significantly (P≤0.05) less likely to be threatening, destroy property, and talk loudly. Also, significantly fewer patients receiving donepezil were treated with sedatives (P≤0.05). These findings support the growing body of evidence that cholinesterase inhibitors have psychotropic properties and reduce behavioral disturbances in patients with AD.